Show simple item record

dc.contributor.authorAydiner, Adnan
dc.contributor.authorYildiz, Ibrahim
dc.contributor.authorSeyidova, Avesta
dc.date.accessioned2021-03-04T11:46:21Z
dc.date.available2021-03-04T11:46:21Z
dc.date.issued2013
dc.identifier.citationAydiner A., Yildiz I., Seyidova A., "Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status", ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, cilt.14, sa.5, ss.3255-3261, 2013
dc.identifier.issn1513-7368
dc.identifier.othervv_1032021
dc.identifier.otherav_74094142-d179-4b41-934e-67ac5e806e25
dc.identifier.urihttp://hdl.handle.net/20.500.12627/79765
dc.identifier.urihttps://doi.org/10.7314/apjcp.2013.14.5.3255
dc.description.abstractBackground: The efficacy of erlotinib is controversial in patients with unknown EGFR mutational status. The aim of this study was to identify the clinicopathological factors that are predictive of erlotinob treatment outcomes for NSCLC patients with unknown EGFR mutational status. Materials and Methods: A retrospective analysis of 109 patients with advanced NSCLC who had previously failed at least one line of chemotherapy and received subsequent treatment with erlotinib (150 mg/day orally) was performed. A Cox proportional hazard model for univariate and multivariate analyses was used to identify the baseline clinical parameters correlating with treatment outcome, expressed in terms of hazard ratios (HRs) and 95% confidence intervals. Results: The median treatment duration was 15 weeks (range, 4-184). The disease control rate was 55%, including disease stability for >= 3 months for 40% of the patients. Median progression-free survival and median overall survival (OS) were 4.2 and 8.5 months, respectively. The Cox model indicated that an Eastern Cooperative Oncology Group performance status (ECOG PS) >= 2 (HR 3.82; p5% (HR 2.05; p=0.034) were independent adverse prognostic factors for OS in NSCLC patients treated with erlotinib. Conclusions: This study suggests that NSCLC patients should be enrolled in erlotinib treatment after a first round of unsuccessful chemotherapy to improve treatment success, during which they should be monitored for intra-abdominal metastasis and weight loss.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleClinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status
dc.typeMakale
dc.relation.journalASIAN PACIFIC JOURNAL OF CANCER PREVENTION
dc.contributor.departmentİstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü
dc.identifier.volume14
dc.identifier.issue5
dc.identifier.startpage3255
dc.identifier.endpage3261
dc.contributor.firstauthorID207440


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record